Collage of ArriVent and Alphamab
Jun 8, 2024, 06:47
ArriVent and Alphamab Partner in $615.5 million collaboration for Novel ADC Cancer Treatments – GeneOnline
GeneOnline shared a post on LinkedIn:
“ArriVent BioPharma and Alphamab Oncology announce a $615.5 million collaboration to develop and commercialize novel antibody-drug conjugates (ADCs) for cancer treatment. This partnership leverages cutting-edge ADC technology and global commercialization expertise.”
Further Reading.
Source: GeneOnline/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 15:32
Nov 13, 2024, 15:29
Nov 13, 2024, 15:25
Nov 13, 2024, 14:55
Nov 13, 2024, 14:47
Nov 13, 2024, 14:43
Nov 13, 2024, 14:37
Nov 13, 2024, 14:05
Nov 13, 2024, 12:13